Diego A. Díaz García, Medical Oncologist, CEO and Founder at CánCare, shared a post on X about recent paper Teja Voruganti and colleagues authored:
“Perioperative therapy is reshaping early-stage oncogene-driven NSCLC.
EGFR+ disease has adjuvant osimertinib – but what about ALK, BRAF, KRAS?
Should TKIs replace or complement chemo-IO?
Molecular testing, MRD, and smarter sequencing are key. More answers coming soon.”
Title: Perioperative Therapy in Oncogene-Driven Non–Small Cell Lung Cancer: Current Strategies and Unanswered Questions
Journal: American Society of Clinical Oncology Educational Book
Authors: Teja Voruganti, Rosalyn Marar, Benjamin Bleiberg, Edoardo Garbo, Biagio Ricciuti, Kaushal Parikh, and Charu Aggarwal
More posts featuring NSCLC on OncoDaily.
